Abstracts tagged "Cardiovascular disease"

Abstract Number: 1442 • 2014 ACR/ARHP Annual Meeting
The 2013 ACC/AHA Cardiovascular Risk Prediction Model and Coronary Atherosclerosis in Patients with Rheumatoid Arthritis
Vivian K. Kawai¹, Cecilia P. Chung², Joseph F. Solus¹, Annette Oeser¹, Paolo Raggi³ and C. Michael Stein¹, ¹Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³University of Alberta, Edmonton, AB, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk of atherosclerotic cardiovascular (CV) disease that is underestimated by the Framingham risk score (FRS). We hypothesized…
Abstract Number: 1275 • 2014 ACR/ARHP Annual Meeting
Association Between Cardiometabolic Disorders and Hand Osteoarthritis Severity: A Cross-Sectional and Longitudinal Study
Alice Courties¹, Jérémie Sellam¹, Francis Berenbaum¹, Emmanuel Maheu¹, Yoann Barthe², Fabrice Carrat² and Christian Cadet³, ¹AP-HP, Saint-Antoine Hospital, Rheumatology Department and DHU i2B, Paris, France, ²Public Health, Saint-Antoine Hospital, Inserm UMRS_1136, UPMC Univ Paris 06, AP-HP, Paris, France, ³Rheumatology, Private office, Paris, France
Background/Purpose Obesity and metabolic disorders increase the risk of hand osteoarthritis (HOA). This study aimed to determine i) clinical and radiographic features associated with HOA…
Abstract Number: 627 • 2014 ACR/ARHP Annual Meeting
HLA Markers for Disease Severity Are Associated with a Higher Burden of Atherosclerosis in Patients with Psoriatic Disease
Lihi Eder¹, Fatima Abji¹, Cheryl Rosen², Vinod Chandran¹ and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Recent evidence supports the link between the extent of inflammation and cardiovascular risk in patients with psoriatic disease (PsD). We aimed to investigate the…
Abstract Number: 2307 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Disease Prevention in Rheumatologic Disease: Assessing Screening in a Primary Care Setting
Micaela Bayard¹ and Magdalena Cadet², ¹Rheumatology, New York Hospital of Queens/ Weill Cornell Medical Center, New York, NY, ²Rheumatology and Immunology, Duke University School of Medicine, Durham, NC
Background/Purpose: To determine the proportion of patients diagnosed with rheumatologic disease receiving preventive health care according to US Preventive Services Task Force recommendations with emphasis…
Abstract Number: 1428 • 2014 ACR/ARHP Annual Meeting
Comparison of Application of the European Society Cardiology, Adult Treatment Panel III, and ACC/AHA Guidelines for Cardiovascular Disease Prevention in a French Cohort of Rheumatoid Arthritis
Martin Soubrier¹, Zuzana Tatar², Maxime Chevreau³, Bruno Pereira⁴, Laure Gossec⁵, P Gaudin⁶ and Maxime Dougados⁷, ¹COMEDRA trial group, Paris, France, ²Centre Jean Perrin, Clermont Ferrand, France, ³Rheumatology, CHU Sud Hospital, Grenoble, France, ⁴Clinical research department, Clermont-Ferrand, France, ⁵Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ⁶CHU Hôpital Sud, Grenoble, France, ⁷RAID working group for EULAR, Zurich, Switzerland
Background/Purpose Cardiovascular risk (CVR) is increased in RA and should be evaluated annually. EULAR recommends using the SCORE equation to calculate risk, after applying a…
Abstract Number: 1274 • 2014 ACR/ARHP Annual Meeting
Patients with Osteoarthritis Do NOT Have Increased Risk of Cardiovascular Disease in Ullensaker Community in Norway
Silvia Rollefstad¹, Ingvild Eeg², Ida K. Haugen², Inge C. Olsen³, Nina Østerås⁴, Barbara Christensen², Hilde Berner Hammer⁵, Lars Nordsletten⁶, Bård Natvig⁷, Tore K. Kvien⁸ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of rheumatology, National Advisory Unit for rehabilitation in rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁶Dept of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway, ⁷General Practice, Oslo University, Oslo, Norway, ⁸Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose Controversies exist regarding whether patients with osteoarthritis (OA) have an increased risk of cardiovascular (CV) disease. Our aim was to evaluate the CV risk…
Abstract Number: 564 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Events in Ankylosing Spondylitis. an Updated Meta-Analysis
Sylvain Mathieu¹ and Martin Soubrier², ¹Hopital Gabriel Montpied, Clermont Ferrand, France, ²Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose: Rheumatoid arthritis is associated with increased cardiovascular risk. In the guidelines, ankylosing spondylitis (AS) is considered to have an equally high cardiovascular risk. The…
Abstract Number: 2308 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Disease Prevention in RA: Compliance Lipid Screening Guidelines
Timothy J Schmidt^1,2, J Antonio Avina-Zubieta^3,4,5, Eric C. Sayre⁴, Michal Abrahamowicz⁶, John M. Esdaile^3,7,8 and Diane Lacaille^9,10,11, ¹Arthritis Research Centre of Canada, Richmind, BC, Canada, ²Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Richmond, BC, Canada, ³Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ⁴Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁵Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁶Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁷Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁹Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁰Arthritis Research Centre of Canada, Vancouver, BC, Canada, ¹¹University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of reduced quality of life and increased mortality in RA. Cardiovascular diseases are the leading cause of…
Abstract Number: 1423 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Risk Estimation in Rheumatoid Arthritis: What Is Missing in Traditional Risk Estimators?
Gulsen Ozen¹, Murat Sunbul², Pamir Atagunduz¹, Haner Direskeneli¹, Kursat Tigen² and Nevsun Inanc¹, ¹Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Department of Cardiology, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: Cardiovascular (CV) disease is one of the major causes of mortality in rheumatoid arthritis (RA). Although the CV risk in RA is well-recognized, detection…
Abstract Number: 1182 • 2014 ACR/ARHP Annual Meeting
Do Patients with Active RA Also Have Inflamed Atherosclerotic Plaques on PET-MRI?
Sarah Skeoch¹, Heather Williams², Penny Cristanacce³, Jacqueline James⁴, Paul Hockings⁵, Yvonne Alexander⁶, John Waterton^7,8 and Ian N. Bruce⁹, ¹University of Manchester, Manchester, United Kingdom, ²Centre for Imaging Sciences Biomedical Imaging Institute, University of Manchester, Manchester, United Kingdom, ³Biomedical Imaging Institute, University of Manchester, Manchester, United Kingdom, ⁴Department of Nuclear Medicine, Central Manchester University Hospitals Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵MedTech West, Chalmers University of Technology, Gottenburg, Sweden, ⁶Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁷R&D Personalised Healthcare & Biomarkers, Astra Zeneca, MACCLESFIELD, United Kingdom, ⁸Bioimaging Institute, University of Manchester, Manchester, United Kingdom, ⁹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Inflammation plays a key role in the progression and destabilisation of atherosclerotic plaque in the general population. In RA, inflammation is thought to accelerate…
Abstract Number: 542 • 2014 ACR/ARHP Annual Meeting
Predictors for Cardiovascular Events in Patients with Psoriatic Arthritis – a Cohort Study
Lihi Eder¹, Arane Thavaneswaran¹, Vinod Chandran¹, Hua Shen², Richard J. Cook² and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose The prevalence of cardiovascular (CV) morbidity is increased in patients with psoriatic arthritis (PsA). CV risk is only partially explained by traditional CV risk…
Abstract Number: 2212 • 2014 ACR/ARHP Annual Meeting
Serum Adipokines in Dermatomyositis: Correlation with Risk Factors Associated to Cardiovascular Diseases and Metabolic Syndrome
Marilda Guimarães Silva, Suzana Beatriz Veríssimo de Mello and Samuel Katsuyuki Shinjo, Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Adipokines are a group of cytokines produced by adipose tissue, which include adiponectin, resistin and leptin. The adiponectin has anti-diabetic, anti-inflammatory and anti-atherogenic effects,…
Abstract Number: 1441 • 2014 ACR/ARHP Annual Meeting
Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function
Torkell Ellingsen^1,2,3, Henriette Jørgensen⁴, Dino Demirovic⁴, Lone Deibjerg⁵, Frank Andersen⁵, Agnete Hedemann-Andersen⁵, Brian Bridal Løgstrup^5,6 and Suresh Rattan⁴, ¹Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark, ²The Danish National Registry DANBIO, Odense, Denmark, ³Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ⁴Laboratory of Cellular Ageing, Institute of Molecular Biology and Genetics, Århus University, Århus, Denmark, ⁵Diagnostic Centre Region, Hospital Silkeborg Denmark, Silkeborg, Denmark, ⁶Cardiology, Skejby Hospital, Århus Universityhosital, Århus, Denmark
Background/Purpose: The cardiovascular comorbidity seen in early treatment naive rheumatoid arthritis (RA) can be considered as an aspect of ´´accelerated aging``. Methods: We investigated cell…
Abstract Number: 1163 • 2014 ACR/ARHP Annual Meeting
Predictors of Cholesterol and Lifestyle Discussions in Rheumatoid Arthritis Visits: Impact of Perceived RA Control and Comparison with Other Prevention Topics
Christie M. Bartels¹, Joanna Wong², Heather Johnson³, Katya Voelker⁴ and Maureen Smith⁵, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Tufts University School of Medicine, Boston, MA, ³Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Univ of Wisconsin School of Medicine and Public Health, Madison, AA, ⁵Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Experts recommend discussing modifiable cardiovascular disease (CVD) risk factors in RA visits. We examined the predictors of discussions about cholesterol and or lifestyle (weight,…
Abstract Number: 489 • 2014 ACR/ARHP Annual Meeting
Rosuvastatin Improves Arterial Stiffness in Patients with Inflammatory Joint Diseases
Eirik Ikdahl¹, Silvia Rollefstad¹, Jonny Hisdal², Inge C. Olsen³, Ingar Holme⁴, Terje R. Pedersen⁵, Tore Kvien⁶ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of biostatistics, epidemiology and health economics, Oslo University Hospital, Oslo, Norway, ⁵Faculty of Medicine, University of Oslo, Oslo, Norway, ⁶Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose Arterial stiffness, as pulse wave velocity (PWV) and augmentation index (AIx) has emerged as early risk markers of cardiovascular disease (CVD) in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.